Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity
about
Clinical Pharmacology and Translational Aspects of Bispecific AntibodiesDisease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.The Promises of Quantitative Proteomics in Precision MedicinePotential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities.Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.Modeling Therapeutic Antibody-Small Molecule Drug-Drug Interactions Using a Three-Dimensional Perfusable Human Liver Coculture Platform.Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.Blinatumomab Pharmacodynamics and Exposure-Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia.Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.
P2860
Q33648086-12CD6D61-75A8-4BC1-A46E-95B0355A3D5DQ33658743-2BBF3FF0-B7D7-4759-A5C2-35845EB9DD85Q37647264-13830370-ECF1-4F1E-8225-80D6B5E488BEQ38714339-C42370F6-8775-4FA8-89A5-6B6D9EB9DD66Q38750643-824A0CD0-92DC-4C63-AD82-F891F9E27B34Q38753955-0487C7A8-D4C8-46A6-B404-D45A8E3F9105Q39128240-32CF868D-93A1-458B-93EE-3F1A94A4C4EFQ42498885-4593701B-5FDF-4C1B-9FCE-760C0182DADAQ47592224-34C691AD-AB2F-4868-9BF0-E581242E2AFDQ50043284-91AED04C-6088-4360-AEFC-7061B5C3E228Q50094018-9AA65EBB-FB70-40A3-B41A-290FDAFE447FQ50120162-174FD195-6130-447F-980C-C38776B0ED75
P2860
Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Physiologically Based Pharmaco ...... ytochrome P450 Enzyme Activity
@ast
Physiologically Based Pharmaco ...... ytochrome P450 Enzyme Activity
@en
type
label
Physiologically Based Pharmaco ...... ytochrome P450 Enzyme Activity
@ast
Physiologically Based Pharmaco ...... ytochrome P450 Enzyme Activity
@en
prefLabel
Physiologically Based Pharmaco ...... ytochrome P450 Enzyme Activity
@ast
Physiologically Based Pharmaco ...... ytochrome P450 Enzyme Activity
@en
P2093
P2860
P356
P1476
Physiologically Based Pharmaco ...... ytochrome P450 Enzyme Activity
@en
P2093
P2860
P304
P356
10.1002/PSP4.12003
P577
2015-08-22T00:00:00Z